99 related articles for article (PubMed ID: 17685920)
1. Liposomal approach towards the development of a longer-acting factor VIII.
Powell JS
Haemophilia; 2007 Sep; 13 Suppl 2():23-8. PubMed ID: 17685920
[TBL] [Abstract][Full Text] [Related]
2. Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia.
Martinowitz U; Luboshitz J; Bashari D; Ravid B; Gorina E; Regan L; Stass H; Lubetsky A
Haemophilia; 2009 May; 15(3):676-85. PubMed ID: 19298381
[TBL] [Abstract][Full Text] [Related]
3. Longer-acting factor VIII to overcome limitations in haemophilia management: the PEGylated liposomes formulation issue.
Di Minno G; Cerbone AM; Coppola A; Cimino E; Di Capua M; Pamparana F; Tufano A; Di Minno MN
Haemophilia; 2010 Jan; 16 Suppl 1():2-6. PubMed ID: 20059562
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A.
Spira J; Plyushch OP; Andreeva TA; Khametova RN
Thromb Haemost; 2008 Sep; 100(3):429-34. PubMed ID: 18766258
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. A randomised, active-controlled, double-blind study.
Powell J; Martinowitz U; Windyga J; Di Minno G; Hellmann A; Pabinger I; Maas Enriquez M; Schwartz L; Ingerslev J;
Thromb Haemost; 2012 Nov; 108(5):913-22. PubMed ID: 23014711
[TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A.
Fukui H; Yoshioka A; Shima M; Tanaka I; Koshihara K; Fukutake K; Fujimaki M
Int J Hematol; 1991 Oct; 54(5):419-27. PubMed ID: 1756252
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of a new recombinant FVIII formulated with sucrose (rFVIII-FS) in patients with haemophilia A: a long-term, multicentre clinical study in Japan.
Yoshioka A; Shima M; Fukutake K; Takamatsu J; Shirahata A;
Haemophilia; 2001 May; 7(3):242-9. PubMed ID: 11380627
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, prophylactic effects, and safety of a new recombinant FVIII formulated with sucrose (BAY 14-2222) in Japanese patients with hemophilia A.
Shirahata A; Fukutake K; Takamatsu J; Shima M; Yoshioka A
Int J Hematol; 2000 Jul; 72(1):101-7. PubMed ID: 10979218
[TBL] [Abstract][Full Text] [Related]
9. Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A.
Powell JS; Nugent DJ; Harrison JA; Soni A; Luk A; Stass H; Gorina E
J Thromb Haemost; 2008 Feb; 6(2):277-83. PubMed ID: 18039351
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of haemostatic efficacy of plasma-derived FVIII by formulation with PEGylated liposomes.
Dayan I; Robinson M; Baru M
Haemophilia; 2009 Sep; 15(5):1006-13. PubMed ID: 19486171
[TBL] [Abstract][Full Text] [Related]
11. Strategies towards a longer acting factor VIII.
Saenko EL; Pipe SW
Haemophilia; 2006 Jul; 12 Suppl 3():42-51. PubMed ID: 16683996
[TBL] [Abstract][Full Text] [Related]
12. A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose.
Rubinger M; Lillicrap D; Rivard GE; Teitel J; Carcao M; Hensman C; Walker I;
Haemophilia; 2008 Mar; 14(2):281-6. PubMed ID: 18194308
[TBL] [Abstract][Full Text] [Related]
13. PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers.
Ivens IA; Baumann A; McDonald TA; Humphries TJ; Michaels LA; Mathew P
Haemophilia; 2013 Jan; 19(1):11-20. PubMed ID: 22913770
[TBL] [Abstract][Full Text] [Related]
14. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
Berntorp E; Windyga J;
Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
[TBL] [Abstract][Full Text] [Related]
15. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
[TBL] [Abstract][Full Text] [Related]
16. Factor VIII half-life and intensity of treatment in hemophilic patients.
Vicente V
Haematologica; 2005 Apr; 90(4):437. PubMed ID: 15820932
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy in bleeding and surgery in von Willebrand patients treated with Fanhdi a highly purified, doubly inactivated FVIII/VWF concentrate.
Hernandez-Navarro F; Quintana M; Jimenez-Yuste V; Alvarez MT; Fernandez-Morata R
Haemophilia; 2008 Sep; 14(5):963-7. PubMed ID: 18624696
[TBL] [Abstract][Full Text] [Related]
18. The future of hemostasis management.
Lillicrap D
Pediatr Blood Cancer; 2013; 60 Suppl 1():S44-7. PubMed ID: 23109347
[TBL] [Abstract][Full Text] [Related]
19. Prolonged effect of a new O-glycoPEGylated FVIII (N8-GP) in a murine saphenous vein bleeding model.
Pastoft AE; Ezban M; Tranholm M; Lykkesfeldt J; Lauritzen B
Haemophilia; 2013 Nov; 19(6):913-9. PubMed ID: 23730746
[TBL] [Abstract][Full Text] [Related]
20. Extending half-life in coagulation factors: where do we stand?
Lillicrap D
Thromb Res; 2008; 122 Suppl 4():S2-8. PubMed ID: 18929522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
